VC-backed GBT goes public
South San Francisco-based Global Blood Therapeutics Inc, a biopharmaceutical company focused on treating blood-based disorders, has raised $120 million for its IPO after pricing its 6 million shares at $20 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "GBT." Morgan Stanley and Goldman Sachs are serving as the lead underwriters. GBT's backers included Wellington Management Company, RA Capital, Deerfield Management, Sabby Capital and Perceptive Life Sciences.
12 August 2015•2 mins read
